Tags : Medicines

Sangamo Signs a Worldwide License Agreement with Novartis to Develop

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis Novartis to get exclusive license rights of ZFP-TFs […]Read More

Elevian’s Launch to Develop Medicines for Longevity and Age-Related Disorders

Shots: Elevian generated a seed funding of $5.5M from investors including WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital among others Its founders focus on regenerative effects of young blood and identified a specific circulating factor GDF11, by experimenting circulatory systems of young and old mice and observed regeneration of many tissues and organs […]Read More